MACK

Q: What is the price of Merrimack Pharmaceuticals (MACK) today?

The price of Merrimack Pharmaceuticals (MACK) today is $ 0.00, with return of 0% compared to the last year. The price of Merrimack Pharmaceuticals (MACK) started the year trading around $ 0.00 and today it is at $ 0.00. Follow the real-time price chart, the historical price of Merrimack Pharmaceuticals (MACK) and international markets.

Q: When does Merrimack Pharmaceuticals (MACK) pay dividends?

Merrimack Pharmaceuticals (MACK) did not distribute dividends in the last year.

Q: Is Merrimack Pharmaceuticals (MACK) worth it?

Currently, Merrimack Pharmaceuticals (MACK) is priced at $ 0.00, with a P/E of 1.06%, representing a deviation of -6,315% from its historical average P/E. In the last year, the stock showed a variation of 0 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 0.00%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Merrimack Pharmaceuticals (MACK) stock?

Investing in stocks of Merrimack Pharmaceuticals (MACK) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Merrimack Pharmaceuticals (MACK) yield today?

The yield of Merrimack Pharmaceuticals (MACK) was 0.00% in the last month, 0.00% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Merrimack Pharmaceuticals (MACK) today, the total investment would be $ 0.00, based on the current price of $ 0.00.If past performance were to repeat, the return on your investment would be:In 1 year: $ 0.00In 5 years: $ 0.00In 10 years: $ 0.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Merrimack Pharmaceuticals Inc.

Price

$ -

return (12m)

0.00%

p/e

1.06

p/bv

0.96

DIVIDEND YIELD

0.00%

price MACK

MACK

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of MACK

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals MACK

review the fundamentals of Merrimack Pharmaceuticals shares

P/E

1.06

Sector: -3.74 Industry: -3.74

P/SALES RATIO (PSR)

Sector: -3.71 Industry: -3.71

P/BV

0.96

Sector: 2.05 Industry: 2.05

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

82.05%

Sector: -63.91% Industry: -63.91%

ROE

90.44%

Sector: -67.36% Industry: -67.36%

ROIC

-1,375.84%

Sector: -1,129.15% Industry: -1,129.15%

NET MARGIN

0.00%

Sector: -41.63% Industry: -41.63%

GROSS MARGIN

0.00%

Sector: 39.39% Industry: 39.39%

OPERATING MARGIN

0.00%

Sector: -41.51% Industry: -41.51%

P/EBITDA

-136.57

Sector: -3.78 Industry: -3.78

P/EBIT

-138.90

Sector: -3.91 Industry: -3.91

P/ASSET

0.87

Sector: 1.49 Industry: 1.49

BVPS

15.83

Sector: 1.73 Industry: 1.73

EPS

14.32

Sector: -2.05 Industry: -2.05

EQUITY RATIO

0.91

Sector: 0.41 Industry: 0.41

CAGR REVENUE 5 YEARS

0.00%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Merrimack Pharmaceuticals ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 0.00

Fair Value

$ 0.00

Upside Return potential.

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals MACK

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	19.36	0.00	0.00%	2.52%	$ 486.25 B	27.26%
PFE	15.06	1.59	10.56%	6.61%	$ 147.98 B	15.65%
ABBV	168.68	-154.98	-91.88%	2.88%	$ 402.80 B	4.00%
NVO	13.80	7.96	57.70%	3.53%	$ 212.69 B	32.78%
MRK	13.09	0.00	0.00%	3.25%	$ 249.10 B	29.63%
AZN	29.76	6.09	20.45%	1.74%	$ 279.74 B	16.17%
BMY	17.58	5.71	32.47%	4.76%	$ 106.18 B	12.57%
GILD	18.58	7.02	37.80%	2.59%	$ 150.68 B	27.88%
ZTS	19.83	9.74	49.11%	1.69%	$ 52.56 B	28.21%
HALO	12.44	14.70	118.17%	0.00%	$ 7.41 B	47.91%
REGN	16.32	2.41	14.79%	0.49%	$ 74.71 B	32.13%
AMGN	25.34	18.45	72.82%	2.85%	$ 177.48 B	19.47%
VRTX	31.73	6.73	21.22%	0.00%	$ 116.60 B	31.35%
MCK	24.84	-173.31	-697.75%	0.37%	$ 100.18 B	1.04%
CAH	29.67	-17.33	-58.40%	1.02%	$ 47.32 B	0.68%
ADMA	22.65	11.00	48.57%	0.00%	$ 4.74 B	42.87%
BIIB	16.57	1.46	8.83%	0.00%	$ 26.65 B	15.98%
HRMY	12.44	2.77	22.24%	0.00%	$ 2.31 B	22.48%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

MACK Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividend	12/16/2019	12/23/2019	0,50070000
Dividend	08/28/2019	09/05/2019	1,49670000
Dividend	05/17/2017	05/26/2017	10,55000000

ABOUT THE COMPANY Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Inc.

Average user rating I10

4.0 (0 people)

United States

32 years

Founded: 1993

2012

Time since IPO - 13 years

294

Employees

The Company Merrimack Pharmaceuticals Inc. (United States), is listed on Nasdaq with a market value of $ 211.82 Millions, having an equity of $ 221.65 Millions.

With a total of 294 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ -, which generated a profit in the amount of $ 200.46 Millions.

As for its main indicators, the Company has a P/E ratio of 1.06, a P/BV ratio of 0.96 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker MACK.

Market cap

$ 211.82 Millions

Net worth

$ 221.65 Millions

US$ 221,650,000.00

Assets

$ 244.32 Millions

US$ 244,320,000.00

Total Shares Outstanding

14.00 Millions

14,000,000

Average Daily Trading Volume

$ 230.73 Thousand

US$ 230,726.92

Sector

Health Care

Industry

Biotechnology

MACK

MACK revenue and profits

Financial Results MACK

DRAG THE FRAME TO SEE MORE DATA

MACK cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 813.80 41,98% (12M)

P/E

24.84

0.37%

ROE

-697.75%

P/BV

-173.31

CAH - Cardinal Health

$ 198.18 70,66% (12M)

P/E

29.67

1.02%

ROE

-58.40%

P/BV

-17.33

JNJ - Johnson & Johnson

$ 211.58 48,72% (12M)

P/E

19.36

2.52%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 100.30 2,85% (12M)

P/E

13.09

3.25%

ROE

0.00%

P/BV

0.00

PFE - Pfizer

$ 25.85 9,78% (12M)

P/E

15.06

6.61%

ROE

10.56%

P/BV

1.59

ABBV - AbbVie

$ 223.32 34,34% (12M)

P/E

168.68

2.88%

ROE

-91.88%

P/BV

-154.98

AZN - AstraZeneca

$ 89.83 37,80% (12M)

P/E

29.76

1.74%

ROE

20.45%

P/BV

6.09

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 813.80 41,98% (12 M)

P/L

24.84

0.37%

ROE

-697.75%

P/VP

-173.31

CAH - Cardinal Health

$ 198.18 70,66% (12 M)

P/L

29.67

1.02%

ROE

-58.40%

P/VP

-17.33

JNJ - Johnson & Johnson

$ 211.58 48,72% (12 M)

P/L

19.36

2.52%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 100.30 2,85% (12 M)

P/L

13.09

3.25%

ROE

0.00%

P/VP

0.00

PFE - Pfizer

$ 25.85 9,78% (12 M)

P/L

15.06

6.61%

ROE

10.56%

P/VP

1.59

ABBV - AbbVie

$ 223.32 34,34% (12 M)

P/L

168.68

2.88%

ROE

-91.88%

P/VP

-154.98

AZN - AstraZeneca

$ 89.83 37,80% (12 M)

P/L

29.76

1.74%

ROE

20.45%

P/VP

6.09

Frequently Asked Questions

What is the price of Merrimack Pharmaceuticals (MACK) today?

The price of Merrimack Pharmaceuticals (MACK) today is $ 0.00, with return of 0% compared to the last year. The price of Merrimack Pharmaceuticals (MACK) started the year trading around $ 0.00 and today it is at $ 0.00. Follow the real-time price chart, the historical price of Merrimack Pharmaceuticals (MACK) and international markets.

When does Merrimack Pharmaceuticals (MACK) pay dividends?

Merrimack Pharmaceuticals (MACK) did not distribute dividends in the last year.

Is Merrimack Pharmaceuticals (MACK) worth it?

Currently, Merrimack Pharmaceuticals (MACK) is priced at $ 0.00, with a P/E of 1.06%, representing a deviation of -6,315% from its historical average P/E. In the last year, the stock showed a variation of 0 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 0.00%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Merrimack Pharmaceuticals (MACK) stock?

Investing in stocks of Merrimack Pharmaceuticals (MACK) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Merrimack Pharmaceuticals (MACK) yield today?

The yield of Merrimack Pharmaceuticals (MACK) was 0.00% in the last month, 0.00% in the last year and 0.00% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Merrimack Pharmaceuticals (MACK) today, the total investment would be $ 0.00, based on the current price of $ 0.00.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 0.00
In 5 years: $ 0.00
In 10 years: $ 0.00

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

MACK

Merrimack Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return of MACK

review the fundamentals of Merrimack Pharmaceuticals shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY RATIO

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

type

Ex - Dividend Date

payment date

value

ABOUT THE COMPANY Merrimack Pharmaceuticals

Merrimack Pharmaceuticals Inc.

United States

32 years

2012

294

PROFIT X PRICE MACK

Financial Results MACK

MACK cash flow

asset growth - MACK

MACK balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

PFE - Pfizer

ABBV - AbbVie

AZN - AstraZeneca

Frequently Asked Questions